Approved for treating advanced melanoma patients with BRAF V600 mutations, drugs like vemurafenib, dabrafenib, and encorafenib serve as oral small-molecule inhibitors that specifically target BRAF kinase. This evidence concerns the gene BRAF and melanoma.